Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial - Quiz - MDSpire

Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial

  • By

  • Chengshui Chen

  • Xinyu Liang

  • Zheng Peng

  • Yan Zou

  • Huijuan He

  • Xiaoyan Zhang

  • Yi He

  • Shixiu Wu

  • May 1, 2026

  • 0 min

Share

Original Source(s)

Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis: A Nonrandomized Clinical Trial

  • by Chengshui Chen, Xinyu Liang, Zheng Peng, Yan Zou, Huijuan He, Xiaoyan Zhang, Yi He, Shixiu Wu

  • May 1, 2026

Related Content

Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

Recurrent IDH-mutant astrocytoma WHO grade 4 diagnosed during pregnancy: case report with literature review